Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IJR vs XBI: how they differ
IJR and XBI hold 3% of their weight in the same names, and XBI returned more over the year.
iShares Core S&P Small-Cap ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, IJR and XBI hold 3% of their money in the same securities at the same weight.
| Holding | IJR | XBI |
|---|---|---|
| KRYSTAL BIOTECH INC | 0.54% | 1.10% |
| PROTAGONIST THERAPEUTICS INC | 0.41% | 1.08% |
| TG THERAPEUTICS INC | 0.40% | 1.09% |
| PTC THERAPEUTICS INC | 0.38% | 1.03% |
| VERACYTE INC | 0.26% | 0.82% |
| CATALYST PHARMACEUTICALS INC | 0.20% | 0.88% |
| ACADIA PHARMACEUTICALS INC | 0.18% | 0.94% |
| ARCUS BIOSCIENCES INC | 0.15% | 0.74% |
| VERICEL CORP | 0.13% | 0.50% |
| ADMA BIOLOGICS INC | 0.11% | 0.61% |
| SAREPTA THERAPEUTICS INC | 0.10% | 0.75% |
| VIR BIOTECHNOLOGY INC | 0.07% | 0.47% |
| Only in IJR | Only in XBI |
|---|---|
| FORMFACTOR INC 0.69% | Apogee Therapeutics Inc 1.49% |
| VIASAT INC 0.68% | Moderna Inc 1.41% |
| MOLINA HEALTHCARE INC 0.66% | Twist Bioscience Corp 1.41% |
| ARGAN INC 0.62% | Oruka Therapeutics Inc 1.38% |
| BRIGHTSPRING HEALTH SERVICES INC 0.61% | Kymera Therapeutics Inc 1.36% |
| ELEMENT SOLUTIONS INC 0.61% | Viking Therapeutics Inc 1.31% |
| MAXLINEAR INC 0.60% | Praxis Precision Medicines Inc 1.29% |
| ESCO TECHNOLOGIES INC 0.50% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| IJR iShares Core S&P Small-Cap ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | S&P SmallCap 600 | SPDR S&P Biotech |
| Total return, 1 year | +19.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +2.4 pts | +46.5 pts |
| Expense ratio | 0.06% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 603 | 150 |
IJR in plain words
IJR is an index equity fund tracking the S&P SmallCap 600. Over the year to Sep 11, 2026 it returned +19.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.06% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 603 positions, with the top ten at 6.0%. It sat 5.5% below its high of Aug 14, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IJR or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, IJR returned +19.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IJR or XBI?
- IJR charges 0.06% a year and XBI charges 0.35%, so IJR is cheaper. Fees come from each fund's prospectus.
- How much do IJR and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of IJR and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 3% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IJR against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/IJR-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources